Glofitamab Shows Benefit Regardless of Prior BTK Exposure in R/R MCL

Commentary
Video

All patient populations benefitted from glofitamab in a phase 1/2 trial, but the design excluded capture of high-risk features present in similar studies.

All patient subgroups with relapsed/refractory mantle cell lymphoma (MCL) appeared to benefit from treatment with glofitamab-gxbm (Columvi), even among groups with or without prior exposure to Bruton’s tyrosine kinase (BTK) inhibitors and those with COVID-19 related events, according to Tycel Phillips, MD.

Phillips, an associate professor in the Division of Lymphoma and Department of Hematology & Hematopoietic Stem Cell Transplantation at City of Hope in Duarte, California, spoke with CancerNetwork® during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting about an analysis from a phase 1/2 study (NCT03075696) evaluating glofitamab monotherapy in patients with heavily pretreated relapsed/refractory MCL.

He highlighted a lack of disparity in outcomes among patient populations who appeared to derive equal efficacy from glofitamab, especially in the post-BTK setting. However, he noted that the trial was not designed to focus on many high-risk disease features that investigators typically report in other MCL studies. According to Phillips, the agent may be usable among country-wide centers accustomed to the use of bispecific antibodies to increase the accessibility of T-cell therapies for MCL.

Transcript:

As of right now, we don’t really have a true subset analysis, but overall, we didn’t see a patient population that did not benefit from it. Unfortunately, as the trial was designed, we didn’t really capture a lot of those high-risk features that typically are present in a lot of these mantle cell lymphoma studies. Overall, [across] the BTK-exposed or BTK-naïve [groups], which are probably the big 2 categories we can separate patients into, we really didn’t see a difference in outcomes again, especially.If we do center some of the COVID-19 related events, it does appear that these patients receive equal efficacy. If you look at a post-BTK setting, this is a very effective drug. A drug that, again, as more centers get used to using bispecific antibodies, is something that can be given throughout the country, and will increase the accessibility of a T-cell directed therapy for all patients with mantle cell lymphoma.

Reference

Phillips TJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): updated analysis from a phase I/II study. J Clin Oncol. 2024;42(suppl 16). doi:10.1200/JCO.2024.42.16_suppl.700

Recent Videos
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Related Content